Dialysis membranes in the year 2000: Performance and biocompatibility

Nephrology Dialysis Transplantation

Volumn 11, Issue SUPPL. 8, 1996, Pages 16-19

  Akizawa, T ^a   Kinugasa, E ^a   Koiwa, F ^a   Kohjiro, S ^a   Ideura, T ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Biocompatibility; Dialysis membrane; Haemodialysis; Performance

Indexed keywords

BETA 2 MICROGLOBULIN; CYTOKINE;

ADSORPTION; BIOCOMPATIBILITY; CONFERENCE PAPER; DIALYSIS MEMBRANE; HEMODIALYSIS; PERFORMANCE; PRIORITY JOURNAL;

EID: 0030450509     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.supp8.16     Document Type: Conference Paper

References (20)

1. Akizawa T, Kinugasa E, Ideura T. Classification of dialysis membrane by performance.. Contrib Nephrol 1995; 113: 25-31
2. 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243-1252
3. 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin 1. J Clin Invest 1994; 93: 521-528
4. 2-microglobulin modified with advanced glycation end products. Kidney Int 1996; 49: 538-550
5. Niwa T, Miyazaki S, Katsuzaki T et al. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int 1995; 48: 711-778
6. 2m with advanced glycation end products as observed in dialysis related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 1996; 49: 861-867
7. 2-microglobulin and its clinical significance. Contrib Nephrol 1995; 112: 145-155
8. Sato Y, Ito K, Amemiya H et al. Clinical effect and biocompatibility of APS polysulfone membrane dialyzer. Jpn J Artif Organs (in press)
9. Hoffmann JK, Hartl WH, Deppisch R et al. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int 1995; 48: 1563-1570
10. Schetz M, Ferdinande P, Berghe D et al. Removal of proinflammatory cytokines with renal replacement therapy: sense or nonsense? Intensive Care Med 1995; 21: 169-176
11. Hiatt WR, Koziol BJ, Shapiro JI et al. Carnitine metabolism during exercise in patients on chronic hemodialysis. Kidney Int 1992; 41: 1613-1619
12. Ueland PM, Refsum H, Brattstrom LA. Plasma homocystein and cardiovascular disease. In: Francis RBJ, ed. Hemostasis and Endothelial Function. Marcel Dekker, New York, 1992; 182-236
13. Bostom AG, Shemin D, Lapane KL et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147-152
14. Borland Y, Brunet P. Morbidity and mortality in hemodialysis: the role of schedules. Artif Organs 1995; 19: 827-831
15. Kaysen GA, Rathore V, Shearer GC et al. Mechanism of hypoalbuminemia in hemodialysis patients. Kidney Int 1995; 48: 510-516
16. Pereira BJG, Snodgrass BR, Hogan PJ et al. Diffusive and convective transfer of cytokine inducing bacterial products across hemodialysis membranes. Kidney Int 1995 47: 603-610
17. Berland Y, Brunet P, Ragon A et al. Dialysis fluid and water: their roles in biocompatibility. Nephrol Dial Transplant 1995; 10(S-10): 45-47
18. Hakim RM. Clinical implications of hemodialysis membrane biocompatibility Kidney Int 1993; 44: 484-494
19. Ishihara K, Fukumoto K, Miyazaki H et al. Improvement of hemocompatibility on a cellulose dialysis membrane with a novel biomedical polymer having a phospholipid polar group. Artif Organs 1994; 18: 559-564
20. Saruhashi M, Watanabe H, Sasaki M. Biocompatibility of vitamin E modified regenerated cellulose. Jpn J Artif Organs 1995; 24: 631-636